CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,489 enrolled
Drug / intervention
Dabigatrandrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03258645
NCT03258645N/ACompleted

Pradaxa Initiation Post-Stroke Study: SITS-Pradaxa 1. A Retrospective Analysis From the SITS-AF Registry on Treatment Initiation of Dabigatran Etexilate in Non-valvular Atrial Fibrillation Patients Hospitalized With Acute Ischemic Stroke

Boehringer Ingelheim·observational·Posted Aug 23, 2017·Updated Jul 9, 2020

In Brief

An observational study evaluating Dabigatran for Atrial Fibrillation. Completed, enrolled 1,489 participants across 1 site.

Detailed Summary

This is an observational study in patients with non-valvular atrial fibrillation (NVAF) presenting to the hospital with a first acute ischemic stroke based on existing data recorded in the SITS International Registry (located in Sweden) by physicians in several European countries, such as Italy, United Kingdom, Czech Republic, Sweden, Germany, Poland, Spain, Finland, Portugal, Slovakia, Denmark, Estonia, Norway Belgium, Hungary, Slovenia, Croatia, Austria, Lithuania, France, Greece, Netherlands, Ireland, Ukraine and Iceland. The aim of this study is to explore the current real world use of dabigatran for stroke prevention in NVAF patients in the post-stroke setting. Secondary data from eligible European patients registered in the SITS registry will be considered; countries of origin are not known a priori.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesSweden

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedAug 23, 2017
Enrollment StartNov 15, 2018
Primary CompletionJun 17, 2019
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 8.9 years ago

Interventions

Dabigatrandrug

Oral anticoagulant (NOAC) thrombin inhibitor